Tim Boris - Moderna Director
| MRNA Stock | USD 108.85 0.96 0.89% |
Director
Mr. Tim Boris is Director of the company. He is an experienced General Counsel and business executive who has served on or been legal advisor to executive and leadership teams in multiple industries. He served as the President of SpendSmart Networks, Inc. from April 19, 2016 until March 2017. Mr. Boris served as General Counsel and Secretary of SpendSmart Networks, Inc. from January 20, 2015 and February 21, 2015, respectively, until March 2017 since 2018.
| Tenure | 6 years |
| Address | 200 Technology Square, Cambridge, MA, United States, 02139 |
| Phone | 617 714 6500 |
| Web | https://www.modernatx.com |
Moderna Management Efficiency
The company has return on total asset (ROA) of (0.1197) % which means that it has lost $0.1197 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2859) %, meaning that it created substantial loss on money invested by shareholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.24. The current year's Return On Capital Employed is expected to grow to -0.26. At present, Moderna's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 23.1 B, whereas Other Current Assets are forecasted to decline to about 83.6 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Ian Clark | AVROBIO | 57 | |
| Rachel King | Novavax | 58 | |
| Chaloemphong Mahawanitwong | Ginkgo Bioworks Holdings | 42 | |
| Andrew Hirsch | Editas Medicine | 47 | |
| Cynthia Collins | Editas Medicine | 54 | |
| Philip Vickers | AVROBIO | 58 | |
| Moncef Slaoui | Intellia Therapeutics | 55 | |
| David Scadden | Editas Medicine | 65 | |
| Phillip Donenberg | AVROBIO | 57 | |
| Chathaphum Khantiwiriya | Ginkgo Bioworks Holdings | 52 | |
| Richard Douglas | Novavax | 64 | |
| Ham Sukjaroenkraisri | Ginkgo Bioworks Holdings | N/A | |
| Elaine Ullian | Vertex Pharmaceuticals | 69 | |
| John Mendlein | Editas Medicine | 56 | |
| Kevin Bitterman | Editas Medicine | 40 | |
| Sitthichai Kesornsombat | Ginkgo Bioworks Holdings | 51 | |
| Alan Garber | Vertex Pharmaceuticals | 62 | |
| Robert Hines | Ginkgo Bioworks Holdings | N/A | |
| Boris Nikolic | Editas Medicine | 47 | |
| Terrence Kearney | Vertex Pharmaceuticals | 63 | |
| JeanFrancois Formela | Intellia Therapeutics | 61 | |
Management Performance
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.12 |
Moderna Leadership Team
Elected by the shareholders, the Moderna's board of directors comprises two types of representatives: Moderna inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Moderna. The board's role is to monitor Moderna's management team and ensure that shareholders' interests are well served. Moderna's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Moderna's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Larn Hwang, Chief Scientific Officer | ||
| Melanie MBA, Chief Officer | ||
| Daniel Geffken, Interim CFO | ||
| Stephane Bancel, CEO Director | ||
| Dave Johnson, Chief Officer | ||
| Lavina CFA, Senior Relations | ||
| Nancy Phelan, Director | ||
| Philip Ranker, Director | ||
| Joseph Ramelli, Independent Director | ||
| Noubar Afeyan, Independent CoFounder | ||
| Donald Williams, Independent Director | ||
| Colleen Hussey, Senior Communications | ||
| Patrick Bergstedt, Senior Vaccines | ||
| Robert Moscato, CEO | ||
| Isaac Blech, Director | ||
| Jerh Collins, Chief Officer | ||
| Juan Andres, Pres Expansion | ||
| Charbel MPH, Senior Science | ||
| Uli Hacksell, Chairman of the Board | ||
| Vuong Trieu, Chairman of the Board, CFO, Treasurer | ||
| Michael French, Chairman, CEO and Pres | ||
| Shannon Klinger, Chief Secretary | ||
| Brad Miller, Chief Officer | ||
| James Mock, Chief Officer | ||
| Erik Emerson, Chief Commercial Officer | ||
| John Reynders, Chief Officer | ||
| Melissa Moore, Chief Board | ||
| Stephen MD, President | ||
| Mihir Munsif, COO | ||
| Amit Shah, CFO | ||
| Tim Boris, Director | ||
| Philippe Calais, Director | ||
| Peter Weinstein, Chief Legal Officer | ||
| Stefan Loren, Lead Independent Director | ||
| Tracey Franklin, Chief Officer | ||
| Eric Teague, CFO | ||
| MD FAAP, Senior Development |
Moderna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Moderna a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.69) % | ||||
| Operating Margin | 0 % | ||||
| Current Valuation | 32.55 B | ||||
| Shares Outstanding | 382.88 M | ||||
| Shares Owned By Insiders | 9.61 % | ||||
| Shares Owned By Institutions | 73.52 % | ||||
| Number Of Shares Shorted | 21.44 M | ||||
| Price To Earning | 6.37 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (12.33) | Revenue Per Share 17.927 | Quarterly Revenue Growth (0.45) | Return On Assets (0.12) |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.